At this study we aimed to detect the prevalence of JAK2 V617F mutation in various myeloproliferative neoplasms (MPNs) that represent a major advance in molecular understanding of CMPN disorders in order to identify its diagnostic value.
In this study we evaluated it's clinical and laboratory correlates in 40 patients with MPNs. The mutation was detected by allele-specific PCR.
The mutation was detected in 8 patients: 80% (8/10) of those with polycythemia vera, 63.6% (7/11) of those with essential thrombocythemia, 62.5% (5/8) of those with chronic idiopathic myelofibrosis and 0% (0/11) of those with chronic myeloid leukemia. The patients carrying the mutation were older (p = 0.003) and have splenomegaly in polycythemia vera group (p = 0.05) but no statistical difference was found between positive and negative JAK2 carriers as regarding HB, TLC ,PLTs count or gender type (P > 0.05).
This study implies that the JAK2–V617F mutation may be useful for the diagnosis, classification and the management of patients with MPDs.